Ranibizumab ELISA (mAb-based)
Enzyme immunoassay for the specific and quantitative determination of free Ranibizumab (Lucentis®) in aqueous humour.
The solid phase (MTP) is coated by a highly specific monoclonal antibody directed against Ranibizumab. Therefore any cross reactivity to the other therapeutical monoclonal antibodies is excluded except for Bevacizumab.
Reference: IG-AB110a
Barcode: 8682754930400
Legal Status: RUO (Research Use Only)
Intended Use: This kit has been developed for the measurement of drug levels in research and diagnostic uses. It is suitable for Therapeutical Drug Monitoring (TDM) purposes.
Assay Design:
Related Documents
Instructions for Use IG-AB110a 804.54 KB
Material Safety Data Sheet (MSDS) IG-AB110a 270.72 KB
Quality Control Certificates
Quality Control Certificate Lot: AB110a-106 298.96 KB
Quality Control Certificate Lot: AB110a-105 124.75 KB
Quality Control Certificate Lot: AB110a-104 138.96 KB
Quality Control Certificate Lot: AB110a-103 296.54 KB
Quality Control Certificate Lot: AB110a-102 139.44 KB
Quality Control Certificate Lot: AB110a-04 79.52 KB
Lucentis® is a trademark of ©2018 Genentech USA, Inc.
The Kit at a glance:
| Required Volume (µL) | 5 |
| Incubation Time (min) | 135 |
| Sample | aqueous humour |
| Package Size | 96 Tests |
| Standard Range (ng/mL, 10x) | 0-300 |
| Detection Limit (ng/mL) | 0,33 |
| Spike Recovery (%) | >95 |
| Shelf Life (years) | 2 |
Standard Curve:
